Madrigal Pharmaceuticals’ stock up 5% as company starts rolling submission for FDA approval of NASH treatment
Madrigal Pharmaceuticals Inc.’s stock MDGL, +4.98% rose 5% Friday after the company said it has started a rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of its resmetirom as a treatment for, nonalcoholic steatohepatitis, or NASH, with liver fibrosis. NASH is a more severe version of nonalcoholic…